Lizzy Rosser

New preprint from the lab! Lactate, a tumor-derived metabolite, blocks B cells from entering tumors and forming tertiary lymphoid structures (TLSs). Congratulations Victoire Boulat - in a great collaboration with Anita Grigoriadis! tinyurl.com/3vvk9kec #Immunology #TLS #CancerMetabolism #Bcells

Selena Gomez has shared her experiences living with #lupus since 2015 - writes Foundation-funded researcher @bcellsrosser.bsky.social for @uk.theconversation.com.

To learn more, you can meet Dr Lizzy Rosser at our New Scientist Live stand (C20) on 18-19 October! shorturl.at/BusFG

Congratulations to our new @fightforsight.bsky.social PhD student Persephone Jenkins (3 days in!) for talking at her first PPIE event today. We are very lucky that Seph will be joining us for four years working on childhood uveitis, B cells and the microbiome 👀

@arrdept-ucldom.bsky.social

Analysis: What is lupus, the condition Selena Gomez is diagnosed with? Dr Elizabeth Rosser (UCL Division of Medicine) explores the symptoms, complications and treatments for lupus, an autoimmune disease which celebrity Selena Gomez suffers from as well as an estimated fi...

Thanks @uclnews.bsky.social for sharing my recent article for the @theconversation.com

www.ucl.ac.uk/news/2025/oc...

What is lupus, the condition Selena Gomez is diagnosed with? The autoimmune disease lupus, which affects mainly women, can have wide-ranging impacts on health and quality of life.

Have been a big fan of the @theconversation.com for a while so was a real please to write this article with them. Thank you to @medresfdn.bsky.social for suggesting me and please do have a read 👇

theconversation.com/what-is-lupu...

Experts call for change of heart on hormone replacement therapy after breast cancer Breast cancer survivors with severe menopausal symptoms should be supported to make an informed decision about whether to have hormone replacement therapy or not, according to an interdisciplinary pan...

Breast cancer survivors with severe menopausal symptoms should be supported to make an informed decision about whether to have hormone replacement therapy or not, according to an interdisciplinary panel of experts including Prof Jayant Vaidya @uclmedsci.bsky.social
www.ucl.ac.uk/news/2025/se...

Proportion of Juvenile Idiopathic Arthritis patients reaching inactive arthritis (active joint count = 0) after six months of early biologic treatment compared to intermediate and late biologic treatment. Proportion of JIA patients reaching inactive arthritis after six months of biologic treatment across three treatment groups: early treatment group (time from symptom onset to biologic start: 0-6 months), intermediate treatment group (7-12 months), and late treatment group (13-24 months). Inactive arthritis was defined as having an active joint count of zero at six months

Nested cohort study within UCAN CAN-DU estimated effect of time from symptom onset to start of biologic in JIA. Early start of biologic therapies in JIA was assoc. w/ higher proportion of patients reaching inactive arthritis within 6 months

Arthritis & Rheumatology
doi.org/10.1002/art....

#Medsky

Great to have this out, and such a pleasure to work together. @smguillaume.bsky.social @cristianbeccaria.bsky.social @iannaconelab.bsky.social

Looking forward to watching this later!

I am so excited to be contributing to the upcoming ‘Medicine at the Crick Event’ @crick.ac.uk… organised by Prof Vinuesa and Prof Lee.. come and join us for what will be a fantastic discussion… @arrdept-ucldom.bsky.social

www.crick.ac.uk/whats-on/med...

⏰ Abstract deadline TOMORROW!

The BSI West of Scotland Immunology Group showcase on Thursday 2 October will feature cutting-edge talks on T cell immunometabolism + helminth immunity, plus the 10th Delphine Parrott memorial lecture. #BSIWSIG25

Submit now 👉 https://bit.ly/4npHBe2

Wooo! So exciting to see our new department building up its reputation slowly…!

Amazing to see so much excellent science conducted over the summer through out Summer Studentship scheme. Congrats to Nina, hopefully just the first of many poster sessions to come...

🔔 Fantastic opportunities to join us as part of the new and exciting @exposomeimmunology.bsky.social
@lydiabeckeriii.bsky.social

Check out the details 👇

Please spread the word! #immunosky

Congratulations to our @thelisterinstitute.bsky.social BSc summer student Nina Bird on her first conference poster presentation at the Lister Institute’s Annual Conference 🎇 Nina has been a joy to have in the lab on this fab scheme!

@merrywilkinsonlab.bsky.social is on BlueSky! Give her a follow now!!!

Space for play is being ‘designed-out’ of urban childhoods Children growing up in British cities face barriers to safe, playable spaces as financial constraints, policy misalignment and housing pressures cause planners to prioritise property over parks, finds...

Children growing up in British cities face barriers to safe, playable spaces as planners prioritise property over parks, find researchers at @ioe.bsky.social, @uclengineering.bsky.social and @bihr.bsky.social.

www.ucl.ac.uk/news/2025/se...

Research breakthrough ‘open doors to new treatments’ for rare muscle disease Children with a rare, debilitating muscle disease could benefit from the findings of new research by experts at UCL and Great Ormond Street Hospital (GOSH).

Children with the rare, debilitating muscle disease juvenile dermatomyositis may benefit from exciting new research by experts including Dr Merry Wilkinson and Professor Wedderburn (UCL Great Ormond Street Institute for Child Health) and at Great Ormond Street Hospital @uclpophealthsci.bsky.social

And the send-off from the cutest helper tradition continues 🥹
Off I go to Basel for what's hopefully an amazing conference all about mucosal lymphocytes 😍
#EMBObarrierTissues
@bcellsrosser.bsky.social

Do you live with an immunodeficiency or have another immune-related condition like asthma or diabetes, or care for someone who does?

Join our new PPI Network to help shape the future of immunology.

Apply by 22 Sept 2025

🔗 More info: https://bit.ly/3Jz7cT6

We're so pleased to support Lizzy's important work!

#ListerFellow @ and Lucy Wedderburn comment on the future of #rheumatology research and argue it's time to prioritise #researchequity and #inclusion so no patient group is left behind.

👀 www.nature.com/articles/s41...

@bcellsrosser.bsky.social @uclchildhealth.bsky.social

Vanishing Y chromosomes seem to be driving heart disease in men Men typically lose Y chromosomes from their cells as they get older, which could be affecting their heart health

Y chromosomes can vanish from men's cells, particularly as they get older, which may be a key driver of heart disease.

Thanks @dianaematei.bsky.social - I loved writing this with Prof Wedderburn in @natrevrheum.nature.com on the back of our new departmental launch @arrdept-ucldom.bsky.social ✨

I told my whole group to write and abstract and register….! Looking forward to see my colleagues and friends there and hoping one of the group gets a travel grant 😹

Interact-omics is a high-throughput cytometry-based framework for cellular interaction mapping. @simonhaas.bsky.social

www.nature.com/articles/s41...

This illustration depicts the changes in the immune system throughout an individual’s life span, from infancy to childhood, adulthood, and older age.

A new special issue of Science explores the immune system at the molecular and cellular level and how it has evolved to govern multiple facets of human health.

Learn more: scim.ag/3IYhnk7

Pathology-oriented multiplexing enables integrative disease mapping - Nature Pathology-oriented multiplexing (PathoPlex) represents a framework for widespread access to multiplexed imaging and computational image analysis of clinical specimens at a relatively high throughput and subcellular resolution.

Nature research paper: Pathology-oriented multiplexing enables integrative disease mapping

go.nature.com/3HdZxZG

Early-life human CD8+ T cells exhibit rapid, short-lived effector responses and a unique transcription factor landscape @lucasite-lab.bsky.social
www.pnas.org/doi/10.1073/...